In a report released on April 3, Edward Woo from Ascendiant maintained a Buy rating on Alzamend Neuro (ALZN – Research Report), with a price target of $6.75. The company’s shares closed yesterday at $0.50.
Woo covers the Healthcare sector, focusing on stocks such as Vivos Therapeutics, Biolase, and Plus Therapeutics. According to TipRanks, Woo has an average return of -1.6% and a 41.03% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alzamend Neuro with a $6.75 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $1.50 and a one-year low of $0.31. Currently, Alzamend Neuro has an average volume of 223.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline of product candidates consist of two novel therapeutic drug candidates namely AL001 a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, and; AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s.
Read More on ALZN:
- Ault Inc. partner Alzamend initiates Phase I/IIa trial for Alzheimer’s vaccine
- Alzamend Neuro inititates Phase I/IIA Trial for LZN002 to treat dementia
- Alzamend Neuro receives Study May Proceed letter from FDA for Alzheimer’s study
- Alzamend Neuro announces completion of clinical portion of Phase IIA MAD trial
